Monopar Announces New Drug Candidate, MNPR-202, And Enters Into Collaboration Agreement With The National University Of Singapore For Preclinical Evaluation In Cancer
Development of novel Camsirubicin analog expands Monopar’s therapeutic pipeline WILMETTE, Ill., June 4 (Bernama-GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has entered into a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore)…

